Your browser is no longer supported. Please, upgrade your browser.
Cellectis S.A.
Index- P/E- EPS (ttm)-2.66 Insider Own- Shs Outstand42.87M Perf Week-2.65%
Market Cap678.57M Forward P/E- EPS next Y-2.85 Insider Trans- Shs Float37.79M Perf Month-5.40%
Income-113.00M PEG- EPS next Q-0.73 Inst Own33.60% Short Float4.04% Perf Quarter-30.71%
Sales58.50M P/S11.60 EPS this Y20.70% Inst Trans-7.06% Short Ratio5.59 Perf Half Y-52.87%
Book/sh6.11 P/B2.41 EPS next Y-29.10% ROA-23.70% Target Price- Perf Year-10.52%
Cash/sh- P/C- EPS next 5Y- ROE-39.10% 52W Range14.18 - 34.71 Perf YTD-45.64%
Dividend- P/FCF- EPS past 5Y-23.40% ROI-22.10% 52W High-56.67% Beta2.36
Dividend %- Quick Ratio5.70 Sales past 5Y5.70% Gross Margin- 52W Low6.06% ATR0.96
Employees340 Current Ratio5.80 Sales Q/Q-46.10% Oper. Margin- RSI (14)44.66 Volatility5.40% 5.52%
OptionableYes Debt/Eq0.41 EPS Q/Q-158.60% Profit Margin- Rel Volume0.63 Prev Close14.71
ShortableYes LT Debt/Eq0.39 Earnings- Payout- Avg Volume272.80K Price15.04
Recom1.70 SMA20-2.23% SMA50-11.12% SMA200-29.31% Volume152,128 Change2.24%
Apr-28-21Downgrade Guggenheim Buy → Neutral
Mar-16-21Upgrade Robert W. Baird Neutral → Outperform $23 → $39
Aug-19-20Upgrade Citigroup Neutral → Buy $15 → $32
May-12-20Initiated Robert W. Baird Outperform $20
Mar-06-20Downgrade Goldman Neutral → Sell $15 → $11
Oct-30-19Resumed Guggenheim Buy $28
Aug-09-19Initiated BTIG Research Buy $37
May-24-19Resumed Citigroup Neutral $22
Mar-14-19Initiated William Blair Outperform
Dec-19-18Initiated Goldman Neutral
Jul-16-18Initiated Barclays Overweight $50
Mar-16-18Initiated Guggenheim Neutral
Sep-05-17Reiterated Wells Fargo Outperform $33 → $40
Sep-05-17Downgrade SunTrust Buy → Hold
Mar-02-17Initiated Instinet Buy $49
Feb-28-17Initiated Wells Fargo Outperform
Apr-05-16Initiated Ladenburg Thalmann Buy $45
Mar-02-16Initiated Sun Trust Rbsn Humphrey Buy
Jul-20-15Initiated BofA/Merrill Buy $50
Apr-20-15Initiated Piper Jaffray Overweight $42
Jun-15-21 07:23AM  
Jun-14-21 04:30PM  
Jun-09-21 04:30PM  
Jun-02-21 02:30AM  
May-26-21 10:53AM  
May-11-21 04:30PM  
May-10-21 04:30PM  
May-06-21 04:30PM  
Apr-29-21 06:25AM  
Apr-26-21 04:39PM  
Apr-12-21 04:30PM  
Apr-09-21 02:30AM  
Mar-30-21 08:06AM  
Mar-29-21 04:50PM  
Mar-12-21 04:30PM  
Mar-05-21 03:30PM  
Mar-04-21 05:22PM  
Feb-25-21 04:30PM  
Feb-16-21 09:23AM  
Feb-10-21 04:30PM  
Jan-15-21 06:12PM  
Jan-06-21 04:30PM  
Dec-17-20 11:58AM  
Dec-15-20 08:16PM  
Dec-14-20 04:19PM  
Dec-08-20 04:30PM  
Dec-07-20 10:42PM  
Dec-05-20 05:00PM  
Nov-18-20 07:29AM  
Nov-17-20 08:00PM  
Nov-16-20 04:30PM  
Nov-06-20 04:30PM  
Nov-05-20 04:35PM  
Nov-04-20 09:18AM  
Oct-21-20 04:30PM  
Oct-16-20 08:26AM  
Oct-13-20 09:45AM  
Oct-07-20 04:30PM  
Sep-07-20 04:30PM  
Sep-02-20 04:56PM  
Aug-05-20 04:30PM  
Jul-29-20 04:30PM  
Jul-21-20 04:30PM  
Jul-10-20 06:04PM  
Jul-07-20 08:17AM  
Jul-06-20 05:19PM  
Jul-05-20 10:28PM  
Jun-30-20 11:30AM  
Jun-29-20 04:30PM  
Jun-25-20 04:30PM  
Jun-10-20 04:30PM  
Jun-08-20 09:05AM  
Jun-03-20 11:30AM  
Jun-01-20 07:56AM  
May-18-20 04:30PM  
May-13-20 09:08AM  
May-12-20 04:30PM  
May-11-20 04:30PM  
May-09-20 02:00PM  
May-08-20 06:00AM  
May-06-20 04:30PM  
Apr-30-20 06:13PM  
Apr-29-20 04:30PM  
Apr-13-20 04:30PM  
Apr-10-20 05:00PM  
Apr-02-20 12:00PM  
Mar-27-20 11:09AM  
Mar-10-20 04:30PM  
Mar-06-20 04:30PM  
Mar-04-20 04:30PM  
Feb-25-20 04:30PM  
Feb-21-20 12:00PM  
Feb-18-20 04:30PM  
Feb-07-20 05:00PM  
Jan-27-20 11:01PM  
Jan-15-20 04:30PM  
Jan-13-20 04:15PM  
Jan-09-20 04:30PM  
Jan-06-20 04:30PM  
Jan-02-20 09:16AM  
Dec-31-19 08:45AM  
Dec-17-19 11:13AM  
Dec-02-19 04:30PM  
Nov-21-19 07:22AM  
Nov-20-19 04:30PM  
Nov-13-19 04:30PM  
Nov-06-19 04:47PM  
Oct-31-19 04:30PM  
Oct-30-19 01:15AM  
Oct-29-19 04:30PM  
Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma; ALLO-316 for the treatment of Renal Cell Carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART22 to treat B-cell acute lymphoblastic leukemia. It is also developing UCARTCS1 and ALLO-715 for the treatment of multiple myeloma. In addition, the company produces high oleic soybean oil, other soybean products, and fiber wheat. It has strategic alliances with Allogene Therapeutics, Inc.; Les Laboratoires Servier; The University of Texas M.D. Anderson Cancer Center; and Iovance Biotherapeutics, as well as a strategic research and development collaboration with Cytovia Therapeutics, Inc. The company was founded in 1999 and is headquartered in Paris, France.